Background. Exposure of infant animals to clinically used anaesthetics is associated with acute structural brain abnormalities and development functional alterations. The a 2 -adrenoceptor agonist dexmedetomidine (DEX) induces sedation, analgesia, and provides neuroprotection in experimental brain injury models. However, it is unknown whether DEX also affords protection in the developing brain against anaesthesia using sevoflurane (SEVO), which is commonly used in paediatric anaesthesia. Methods. Infant rats were exposed on postnatal day seven for six h to 2.5% SEVO and were given i.p. injections of saline or DEX (1-50 mg kg À1 ) three times during the exposure. Level of anaesthesia, respiratory rates, and arterial blood gasses were
later in life. 4 7-11 Neurotoxic and cognitive alterations have been documented in several species from rodents to non-human primates, and there is concern that infants and children could be affected if they are exposed for long periods or on multiple occasions to general anaesthesia. [12] [13] [14] [15] For this reason, the Food and Drug Administration (FDA) of the United States in December 2016 issued a warning for the repeated or lengthy use of general anaesthetics and sedation drugs in young children or in women in their third trimester of pregnancy, as a result of concerns for possible negative alterations in brain development. 16 Because general anaesthetics and sedatives are necessary for surgery and other procedures, a search for approaches that could ameliorate the neurotoxic effects of anaesthetics is of utmost clinical importance. Dexmedetomidine (DEX) is a potent a 2 -adrenoceptor agonist that has sedative, analgesic, and anxiolytic effects. 17 Its major clinical use is in the intensive care unit (ICU) and as an adjunct to general anaesthesia to reduce anaesthetic doses, provide analgesia and sedation in the preoperative and postoperative period, and to expedite extubation. [18] [19] [20] Importantly, DEX has been increasingly used in paediatric medicine, despite the lack of paediatric labelling, because the drug possesses many properties that are advantageous for paediatric sedation. [21] [22] [23] [24] DEX produces its sedative effects by acting on sleep pathways at the locus coeruleus similar to the induction of natural sleep and independent of interactions with NMDA or GABA A receptors. 25 26 A unique feature of DEX is that its beneficial effects are not accompanied by significant respiratory depression, which is typical of other commonly used sedatives such as benzodiazepines, propofol, and opioids. 20 In addition, DEX is especially useful in infants and children because of its properties of rapid sedation and recovery together with less irritation of the airway. 27 There is increasing evidence that DEX has organ protective properties in several injury models including ischaemiareperfusion, inflammation, and traumatic brain injury. [28] [29] [30] [31] [32] More recently, DEX has been shown to be protective against neurotoxicity induced by ketamine and isoflurane in a neonatal rat model. 33 34 Sevoflurane (SEVO) is the preferred and most frequently used volatile anaesthetic in paediatric anaesthesia. 35 36 SEVO produces sedation by interacting with several targets including GABA A and NMDA receptors. 37 38 In the neonatal rat model, a single exposure to SEVO (2 to 3% for four to six h) leads to widespread neuronal apoptosis in several brain regions and causes long-term behavioural impairments and memory dysfunction. [39] [40] [41] [42] [43] [44] Whether DEX can ameliorate neurotoxicity induced by SEVO has not been investigated. Consequently, the aim of this study was to investigate the protective potential of DEX for SEVO-induced neurotoxicity in a neonatal rat model. We found that DEX reduced SEVO-induced apoptosis in several brain regions when used at low doses (1 mg kg À1 ) that are comparable with those used in clinical practice. However, co-administration of DEX at higher doses (5 mg kg À1 and above)
during SEVO anaesthesia increased mortality in this experimental model.
Methods

Ethical approval
All procedures involving animals were conducted according to criteria approved by the Institutional Animal Care and Use Committee (IACUC) at Oregon Health & Science University (Portland, OR, USA).
Experimental animals
Timed pregnant Wistar rats were purchased from a commercial breeder (Charles River, Hollister, CA, USA) and kept in individual cages under a 12-h light-dark cycle (lights on from 07:00 to 19:00), with access to standard lab chow and water ad libitum. The day of birth was designated as post-natal day zero (P0). Litters were culled to 10 animals on P1 or P2 to reduce infant rat size variability caused by insufficient nutrition.
Exposure to anaesthesia and dexmedetomidine P7 infant rats of both sexes were exposed to 2.5% SEVO in 30% oxygen (vol%, balance N 2 ) or 30% oxygen (control) for six h via continuous flow in an incubator (ThermoCare Portable Small Animal Intensive Care System Unit, Incline Village, NV, USA) with the interior floor level temperature maintained at 35 C.
We have shown that this floor temperature results in rectal temperatures of 37.0 to 37.5 C in P7 infant rats. 45 The chamber outflow oxygen and SEVO concentrations were continually monitored by a POET 1Q anaesthesia gas monitor (Criticare technologies, INC, North Kinstown, RI, USA). Temperature in the chamber was monitored by a DeBusk temperature system (Debusk Technology corporation Inc, New Tazewell, TN, USA). Pups were given intraperitoneal (i.p.) injections of dexmedetomidine hydrochloride (DEX, Mylan Institutional LLC, Rockford, IL USA) at doses of 1, 5, 10, 25, or 50 mg kg À1 in a volume of approximately 0.1 ml (range 0.09-0.13), or an equal volume of vehicle (0.9% saline), immediately before being placed in the anaesthetic chamber (0 h) and at two and four h after onset of anaesthesia. Both SEVO-exposed and control infant rats received i.p. injections of DEX or vehicle after they were assessed for anaesthesia depth.
Depth of anaesthesia assessments and respiratory rate monitoring
The level of anaesthesia/responsiveness was assessed by toe pinch and righting reflex scores before being placed in the incubator and at two, four and six h of anaesthetic exposure. A toe pinch test was performed first, and the response was scored on a scale of 1 to 5 as follows: 1¼no spontaneous activity, no response to toe pinch; 2¼no spontaneous activity, single limb withdrawal to pinch; 3¼no spontaneous activity, purposeful movement to toe pinch; 4¼moving spontaneously but slowly and irregularly; and 5¼fully awake, moving regularly and spontaneously. The righting reflex was then evaluated by placing the infant rat in the supine position and observing whether and how it was able to turn prone. The righting reflex was scored on
Editor's key points
• The ability of dexmedetomidine to protect against sevoflurane-induced neurotoxicity was tested in neonatal rats.
• Dexmedetomidine or sevoflurane alone, at general anaesthetic doses, did not increase mortality of infant rats.
• Co-administration of dexmedetomidine dose-dependently reduced sevoflurane-induced neurotoxicity in a brain region-selective manner.
• Despite reducing neurotoxicity, the combination of sevoflurane and dexmedetomidine led to hypercarbia, acidosis, and increased mortality in this animal model. a 1 to 5 scale as follows: 1¼complete loss of righting reflex, no response to being placed in supine position; 2¼uncoordinated movements and unable to return to prone position in 30 s; 3¼uncoordinated movements initially but able to return to prone position in 30 s; 4¼coordinated movements, returns to prone position in less than 10 s, 5¼awake, returns to prone position immediately. Respiratory rate was determined via the observation of abdominal movements for 30 s at each of the indicated time points. All anaesthetic level assessments and respiratory rate measurements were performed by the same investigator.
Euthanasia, blood gases analysis, and brain fixation 
Histopathology
Sections were cut at a thickness of 6 mm through the entire forebrain. Three sections, 36 mm apart, were collected at three different brain levels (frontal, medium, and dorsal), corresponding to figures 23, 43, and 55 in the P7 rat brain atlas by Khazipov et al.
46
Sections were stained for activated caspase-3 (AC-3), a key executioner of programed cell death (apoptosis) that has been extensively characterised in brain cells of infant rats. 47 Deparaffinised sections were heated in 10 mM citrate buffer (pH 6.0) in a steamer for 30 min for antigen retrieval. All rinses were with Tris-buffered saline (TBS) (pH 7. 
Quantification of activated caspase-3 positive cells
Whole histological slides, coded and consisting of the entire tissue slice cut from each brain level, were scanned at a magnification of 20X using a slide scanner (Zeiss Axio Scan Z1 and ZEN software, Carl Zeiss, Oberkochen, Germany). This scanner captures and combines high-resolution microscope images to produce a single high-quality "virtual slide". These virtual slides were stored as high-resolution images in "CZI" file format and saved in a hard drive for subsequent analysis. We used "ZEN 2.3 lite" software (free version) to select brain regions of interest (ROI) in each virtual slide and create individual TIFF images used for quantification of AC-3 positive cells. To prevent bias in ROI selection, the procedure was performed on the whole histological slide using low magnification, at which the AC-3 stained cells were not visible. We created single ROIs for each selected brain region according to the anatomical coordinates for each of the brain levels. 46 AC-3 positive cells were automatically recognised and counted in the ROIs using a customised macro (computer routine) that runs in ImageJ (vs 1.51h, FIJI) software.
The number of AC-3 profiles in each ROI was divided by the ROI area to calculate the density of AC-3 positive cells, expressed as AC-3 cells mm À2 . Selection of ROIs, computer-performed AC-3 cell counts, and AC-3 cell density calculations were performed by an investigator blinded to animal group assignment.
Statistical analysis
Statistical data analysis and tests were performed in Excel (Microsoft) using either built-in functions or the Excel add-on "real statistics resource pack" (freely available for download). Data were tested for normality using the Wilk-Shapiro test. Anaesthesia depth scores are presented median and interquartile range (IQR). Comparison between medians was determined using the non-parametric test Kruskal-Wallis test followed by Dunn's post-hoc test. Respiratory rate, blood gas parameters, and AC-3 cell density data are presented as mean SEM, and comparison between mean was determined using one-way ANOVA followed by Dunnett's post hoc test. For all statistical tests, significance was accepted when P<0.05.
Results
Exposure to SEVO and DEX induced deep anaesthesia, respiratory rate depression, and alteration of physiological homeostasis in a neonatal rat model
The depth of anaesthesia caused by exposure of P7 infant rats to 2.5vol% SEVO and/or DEX for six h was scored (1-5 range) for the toe pinch response and righting reflex. SEVO either alone or with co-administration of DEX (1-5 mg kg À1 ) induced a surgical plane of anaesthesia (test scores of 1 for both toe pinch response and righting reflex) that was maintained throughout the six h exposure (Table 1 ). In contrast, DEX (5-50 mg kg
À1
) alone did not alter significantly toe pinch response scores and slightly decreased righting reflex scores compared with those obtained before DEX administration. Respiratory rates (Table 1 , bottom rows) in all animals exposed to SEVO decreased significantly. In animals co-administered SEVO and DEX, the decrease in respiratory rates during exposure was more pronounced than in the animals exposed to SEVO alone. In contrast, in control animals and in those treated with DEX 5 mg kg À1 alone, respiratory rates were maintained constant throughout the experiment, whereas in animals treated with DEX 25 and 50 mg kg À1 alone, respiratory rates slightly decreased.
Terminal arterial blood gas (ABG) analysis (Table 2) shows that infant rats anaesthetised with SEVO 2.5 vol% with or without DEX have decreased pH, elevated Pa CO 2 , and decreased base excess (BE) compared with controls. The decreased pH and elevated Pa CO 2 were more pronounced in animals exposed to SEVO with DEX 1 and 5 mg kg À1 . In contrast, we did not find significant differences in arterial blood pH, Pa CO 2 and BE between controls and the animals treated with DEX alone (5-25 mg kg À1 ;
BE values from a few animals were not available because of technical reasons, and consequently, errors were not calculated for the affected groups). Finally, glucose and haemoglobin (Hb) concentrations were not significantly different between controls and animals treated with either SEVO and/or DEX ( Table 2) .
Co-administration of high doses of DEX with SEVO increases mortality of infant rats
Exposure of infant rats to SEVO 2.5 vol% alone for six h or administration of DEX alone (5, 25, or 50 mg kg À1 ) did not increase mortality. However, co-administration of DEX with SEVO exposure caused a dose-dependent increase in mortality (Table 3 ). In the SEVO plus DEX 1 mg kg À1 group, we had 22% mortality with 2 of 9 animals that died at six h of exposure. In the SEVO plus DEX 5 mg kg À1 group, mortality increased to 55% and the time of death during exposure was reduced to four or five h for most of the animals that died. Co-administration of DEX 10 mg kg À1 or DEX 25 mg kg À1 with SEVO caused 100% mortality, with most animals dying as early as two or three h after exposure onset. Notably, in the last two groups, animals that died at two or three h of exposure received only one or two DEX doses, respectively. As co-administration of DEX at 10 and 25 mg kg À1 with SEVO was lethal for all infant rats, we decided not to analyse brain cell apoptosis in these groups.
DEX protects against apoptosis caused by SEVO exposure in several brain regions
Apoptotic cell density (AC-3 cells mm À2 ) increased $10-fold in several brain regions at the end of a six h exposure to SEVO 2.5 vol%, compared with that in animals maintained without anaesthesia (controls) (Figs 1-3) . In animals treated with DEX alone (5, 25 or 50 mg kg À1 ) we found a slight increase in apoptosis with respect to controls. This increase did not reach statistical significance in most brain regions, with the exception of the CA1 region of the hippocampus in which we observed a 3-fold increase in AC-3 profiles in animals treated with DEX 50 mg kg (20) 166 (13) 142 (8) 117 (9) 151 (12) 149 (12) 161 (10) 2 h 147 (12) 165 (16) 121 (9) 117 (9) 74 (16) ) reduced SEVO-induced apoptosis by 70% on average in rats that survived the six h exposure to SEVO plus DEX.
À1
We observed regional differences in both the degree of SEVO-induced apoptosis and DEX-induced protection. Two frontal cortical regions analysed, cingulate cortex and primary motor cortex (Fig. 1) , showed only average or below average vulnerability to SEVO and to the protective effects of DEX. SEVO-induced apoptosis by 46% and 59% in cingulate cortex and by 45% and 76% in primary motor cortex, respectively. Regional variability was more pronounced in the central brain levels (Fig. 2) . While some regions (hippocampus CA1 and CA3 regions) appeared more resistant, others showed average (somatosensory cortex) or high sensitivity (thalamus and caudate putamen) to SEVO-induced apoptosis and DEX-induced protection. With respect to controls, SEVO exposure increased apoptosis seven-fold (from 9.0 [1.8] decreased SEVO-induced apoptosis by 53% and 82% in the CA1 region, by 45% and 60% in the CA3 region, by 50% and 73%, in the somatosensory cortex, by 84% and 94% in the thalamus, and by 61% and 72% in the caudate putamen, respectively.
In the two regions analysed at the dorsal brain level, retrosplenial and parietal corticies (Fig. 3) , sensitivity to SEVO or protective effect of DEX were at or above average compared with the rest of the brain. In particular, SEVO increased apoptosis 11-fold (from 5. Together, these results demonstrate that six h of exposure of infant rats to SEVO 2.5 vol% anaesthesia induced robust increases in apoptosis in several cortical and subcortical brain regions compared with controls (no anaesthesia), and that co-administration of DEX (1 or 5 mg kg
) provides significant protection against the neurotoxic effects of SEVO.
Discussion
SEVO is the preferred anaesthetic for use in paediatric medicine, 35 36 and is also used for maintenance of anaesthesia during surgery in pregnant woman in their third trimester and during Caesarean delivery. 48 49 Young children and foetuses are at particular risk for possible neurotoxic effects to the developing brain undergoing synaptogenesis caused by prolonged or repeated general anaesthesia. 16 DEX, which is used in patients of all ages for its sedative and anxiolytic effects, also has organ protective properties in several brain injury models. Accordingly, we investigated the protective potential of DEX against SEVO-induced apoptosis in several brain regions of the neonatal rat. DEX, when used at doses similar to those used in paediatric and obstetric medicine (i.e. 1-5 mg kg
À1
), provided protection against the neurotoxic effects of SEVO anaesthesia in the developing rat brain. In contrast, higher doses of DEX in combination with SEVO anaesthesia were lethal for infant rats.
Exposure of neonatal (P7) rats to SEVO 2.5 vol% induced a surgical plane of anaesthesia as evident by complete loss of righting reflex and lack of response to toe pinch stimulation. This level of anaesthesia was accompanied by a significant decrease in respiratory rate and associated decrease in pH, elevation of Pa CO 2 , and decrease in BE by terminal arterial blood gas analysis. SEVO is known to depress respiration at anaesthetic doses. 50 SEVO causes reduction of presynaptic glutamatergic excitation and enhancement of GABA A ergic inhibition in medullary respiratory and phrenic motor neurones. [51] [52] [53] [54] In isolated brainstem-spinal cord of neonatal rats, SEVO decreased inspiratory activity (burst rate and amplitude in C4 nerve) by a GABA Areceptor dependent mechanism. 55 Our results are consistent with a previous study in spontaneously breathing adult rats anaesthetised with SEVO, that showed similar decreases in respiratory rate (up to 30 breaths min
) and increases in Pa CO 2 (from 59 to 92 mm Hg). 56 However, our results differ from other reports that show that SEVO anaesthesia did not significantly change ventilation, pH, and Pa CO 2 in spontaneously breathing infant rats, 44 57 despite the well-documented respiratory rate depression caused by SEVO in several species. 50 We found that administration of DEX alone, at doses of 25 mg kg À1 and above, caused minor decreases in respiratory rate and small alterations in blood gas parameters. These results are consistent with previous reports showing a small decrease in respiratory rhythm generation in vitro in newborn rats 58 and with mild effects on respiratory rate in dogs treated with DEX alone or in combination with isoflurane. 59 Our results are also consistent with the absence of adverse effects on respiratory rate and blood gas parameters in patients treated with DEX post-surgery in the ICU. 60 Exposure of infant rats to SEVO 2.5 vol% for six h significantly increased apoptosis measured by AC-3 immunohistochemistry in several brain regions including cortical and subcortical areas at different brain levels. To quantify cells positively stained with AC-3 antibody, we developed and used a computerised approach that automatically recognises and Table 3 Mortality of infant rats as a function of DEX dose in animals exposed or not to SEVO. P7 infant rats were exposed to SEVO 2.5 vol%, oxygen 30% or to oxygen 30% (control) for six h and injected three times (before exposure and at two and four h during exposure) with DEX at the indicated doses or vehicle (0.9% saline). DEX (5-50 mg kg À1 ) alone did not increase mortality, but when used in combination with SEVO 2.5 vol%, DEX dose-dependently increased mortality counts AC-3 profiles in digitalized images of histological slides along with the tissue area. This method allows unbiased determination of apoptotic cell density in selected brain areas. Using this approach, we found that SEVO increased AC-3 positive cell density in all brain areas studied by approximately 10-fold on average with respect to controls. These results are consistent with previous studies that show robust increases in apoptotic cells in neonatal animals exposed to SEVO or to isoflurane or desflurane for four to six h at concentrations that induce a surgical plane of anaesthesia. Our results show that co-administration of low doses of DEX to SEVO exposed infant rats significantly decreased apoptosis in all brain areas examined, indicating that DEX provides some protection against SEVO-induced neurotoxicity. The major protective effect of DEX was in the thalamus, and this coincided with the brain region most sensitive to the toxic effects of SEVO. The lowest protective effect of DEX was observed in the primary motor cortex. Our finding that low doses of DEX provide protection against neurotoxic effects of SEVO are consistent with a previous study showing DEX decreased neuronal apoptosis induced by isoflurane in a neonatal rat model. 63 In their study, Sanders and coworkers found that DEX (1-25 mg kg À1 ) dosedependently decreased isoflurane-induced apoptosis in a cortical region, hippocampus and thalamus. They also found the largest protection (92% and 97% with DEX 1 or 25 mg kg
, respectively) in thalamus and the lowest (31% and 52% with DEX 1 or 25 mg kg À1 , respectively) in cortex. 63 A subsequent study by the same group found that escalating DEX doses from 25 to 50 and 75 mg kg À1 did not afford increased protection to isofluraneinduced apoptosis. 33 From these studies, we can conclude that ) in infant rat brain was accompanied by a decrease in phosphorylation of the prosurvival kinases AKT and GSK-3b suggesting that such high doses of DEX can activate neuroapoptosis by stimulating the AKT/GSK 3b signaling pathway. Interestingly, in the DEX 50 mg kg À1 group we found a significant increase in apoptosis in the CA1 region of the hippocampus. A high sensitivity of the CA1 region of the hippocampus to DEX has also been observed in neonatal mice treated with DEX 50 mg kg À1 alone, 67 suggesting that this region is particularly sensitive to high doses of DEX in the developing brain. However, Pancaro and colleagues 65 found that DEX alone (30 or 45 mg kg À1 ) induced significant apoptosis in sensorial cortical regions including the S1 region but not in the hippocampus. Of all areas analysed, the thalamus appears the most resistant brain region to the toxic effects of higher doses of DEX. An unexpected finding was that co-administration of DEX with SEVO caused a dose-dependent increase in infant rat mortality. At DEX doses of 5 mg kg À1 55% of animals died after five h of exposure to SEVO, and escalation to 10 mg kg À1 DEX in SEVO exposed animals caused 100% mortality with 75% of the animals dying at three h of exposure or earlier. These results sharply contrast with those obtained in infant rats anaesthetised with isoflurane (0.75%) and treated with DEX using an identical protocol (i.p. injections at zero, two, and four h after the initiation of isoflurane exposure), in which all animals survived DEX co-administration at doses of 1, 5, 10, 25, 50, and 75 mg kg À1 . 33 63 Similarly, our results contrast with a previous report showing that DEX at 25 mg kg À1 co-administered with ketamine in infant rats did not cause mortality and provided protection against ketamine-induced neuroapoptosis. 34 Similar to results reported by Sanders and colleagues , we did not find significant mortality in infant rats treated with DEX alone at any dose tested (up to 50 mg kg À1 ). 63 This suggests that in the neonatal rat model, DEX can induce animal mortality when co-administered together with SEVO. A similar study, conducted in a different laboratory, investigated the neurotoxic effects of SEVO and DEX in the developing brain of the rat; the results of that are presented in a companion paper in this issue of the British Journal of Anaesthesia. 
